Overview of Climaston

Property	Description
Active ingredients	Estradiol (as 17β-Estradiol) and Dydrogesterone
Form	Film-coated tablets, taken orally
Pharmacological class	Hormone Replacement Therapy (HRT), sequential combination
General purpose	Alleviating symptoms of estrogen deficiency
Origin	Combined (Bio-identical Estradiol, Synthetic Dydrogesterone)

Climaston: A Definition and Pharmacological Classification

Climaston is a prescription-only medicine classified as a Hormone Replacement Therapy (HRT), intended for systemic use in postmenopausal women. It belongs to the broader pharmacological group known as Sex hormones and modulators of the genital system, categorized under the World Health Organization's (WHO) ATC code G03FA: Progestogens and oestrogens, fixed combinations. The drug is defined by its specific two-stage cyclical action and is consistently manufactured as film-coated tablets for oral administration. This combined classification identifies Climaston as the necessary form of hormonal therapy for women who still possess an intact uterus.

Dual Composition: The Role of Estradiol and Dydrogesterone

The two active ingredients in Climaston are Estradiol and Dydrogesterone. Estradiol provides the estrogen component and is chemically identical to the primary estrogen naturally produced by the human body. The counterbalancing agent, Dydrogesterone, is a synthetic progestogen (a retroprogesterone) known for its high selectivity for the progesterone receptor. The combination ensures a crucial dual function: while the Estradiol addresses systemic estrogen deficiency, the Dydrogesterone component provides essential endometrial protection. The progestogen is included to counteract the risk of endometrial hyperplasia associated with unopposed estrogen therapy.

General Purpose: Relief for Postmenopausal Symptoms

The overarching purpose of Climaston is to provide comprehensive hormonal supplementation to mitigate the severe systemic symptoms directly resulting from estrogen deficiency during the postmenopausal period. By supplying these vital, declining hormones, the medication aims to restore physiological balance. The final design of the sequential combination of Estradiol and Dydrogesterone ensures that effective relief from menopausal discomfort is achieved while maintaining the crucial safeguard for the uterine lining.

What side effects are possible with Climaston?

Possible Side Effects and Safety Information

The safety profile for this estradiol/dydrogesterone combination is classified based on frequency and the organ systems affected, as documented in regulatory prescribing information. The adverse reactions range from very common, non-serious effects to rare but serious systemic risks, consistent with the use of systemic combined Hormone Replacement Therapy (HRT).

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions include headache, abdominal pain, and breast pain/tenderness, which are classified as Very Common (may affect more than 1 in 10 patients). Common effects (up to 1 in 10 patients) include symptoms across various systems, such as depression, dizziness, nausea, flatulence, and general conditions like edema and weight changes.

Serious Systemic Safety Risks

Official labeling documents an increased risk of certain serious conditions associated with combined estrogen-progestogen use, especially with long-term exposure. These documented risks include an increased risk of Venous Thromboembolism (VTE), stroke, and breast cancer. Furthermore, an increased risk of probable dementia has been reported in postmenopausal women aged 65 years and older taking estrogen plus progestin therapy. The addition of dydrogesterone is intended to mitigate the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy in women with an intact uterus.

Time-Related Patterns and Constraints

The likelihood of certain adverse effects is linked to the timing of use. Breakthrough bleeding and spotting are frequently noted as more likely during the initial months of treatment (the first 3 to 6 months). The elevated risk of VTE is primarily observed during the first year of HRT. The drug is contraindicated in specific health states, including a history of meningioma, active liver disease, or known thrombophilic disorders.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory documents for the combined components of Climaston (estradiol and dydrogesterone) provide specific guidance regarding the recognition and management of an overdose.

Documented Overdose Presentations

Symptoms reported in association with an overdose of the active substances are generally not serious. The known clinical manifestations include disturbances in the gastrointestinal and reproductive systems:

Nausea
Vomiting
Withdrawal bleeding (in women)

These symptoms, while uncomfortable, are the established indicators of overexposure noted in official labeling.

Emergency Actions and Management

In the event of an overdose, the treatment required is defined by official sources as strictly symptomatic and supportive. No specific antidote for the active substances is available or officially labeled. Medical assessment is advised to manage symptoms and provide necessary supportive care. Because the documented manifestations are typically mild and not life-threatening, the focus of medical attention is on general support of vital functions until the effects subside.

When to Seek Urgent Help: Although the expected symptoms are generally mild, any suspicion of an overdose warrants contact with a healthcare professional or a national poison control center for guidance on supportive management and monitoring.

Therapeutic Uses of Climaston

What Climaston Treats: Main Uses and Benefits

Climaston is commonly used as Hormone Replacement Therapy (HRT) to help with symptomatic relief caused by estrogen deficiency in postmenopausal women. The medication is applied across domains where additional symptomatic support is appropriate, primarily addressing moderate-to-severe vasomotor symptoms, discomfort from genitourinary atrophy, and prevention of postmenopausal osteoporosis in high-risk patients.

The core benefit contributes to easing the overall symptom load, particularly when symptoms interfere with daily functioning. It is relevant for managing groups of symptoms that may become intense or disruptive, such as frequent hot flashes, night sweats, vaginal dryness, and pain during intercourse (dyspareunia). It also plays a role in managing conditions characterized by periods of heightened symptoms, providing supportive skeletal protection for those at high fracture risk.

“This support helps ease the overall burden of symptoms, contributing to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Vasomotor Symptoms
This therapy assists in easing the impact of hot flashes and night sweats, supporting the patient during difficult episodes by easing distress and contributing to more comfortable sleep.

Regulatory References

Haute Autorité de Santé

Eligibility and Restrictions for Use

The use of Climaston is strictly defined by official regulatory guidelines to ensure appropriate population eligibility. The medicine is intended solely for postmenopausal women who still possess an intact uterus. Use is not recommended for pediatric or adolescent populations, as there is no relevant indication, and experience is limited in women older than 65 years.

This medication is absolutely contraindicated (must not be used) in individuals presenting with specific, high-risk conditions, as listed in official regulatory labeling. Use is also contraindicated during both pregnancy and lactation.

Populations Excluded by Contraindication

Known, past, or suspected breast cancer or any oestrogen/progestogen-dependent malignant tumours.
A history of venous thromboembolism (VTE), arterial thromboembolic disease (e.g., stroke or heart attack), or known thrombophilic disorders.
Acute liver disease or previous liver disease with abnormal function tests.
Undiagnosed genital bleeding or untreated endometrial hyperplasia.

What should I know about interactions with other medicines?

Climaston (estradiol and dydrogesterone) can interact with several types of medicines, potentially leading to a decrease in its effectiveness or an increase in the concentration of the hormones in the body, which may elevate the risk of side effects.

Decreased Effectiveness of Climaston

Certain drugs can increase the metabolism of the active ingredients in Climaston, leading to lower levels in the blood and thus potentially reducing the therapeutic effect. These include enzyme-inducing medicines such as:

Anticonvulsants: Phenytoin, carbamazepine, and phenobarbital.
Anti-infectives: Rifampicin (for tuberculosis), and some antivirals (e.g., ritonavir, efavirenz).
Herbal Remedies: Products containing St. John's wort (Hypericum perforatum).

Potential for Increased Effects of Other Medicines

Climaston can affect the way other drugs are processed by the body. For example, it may increase the levels of:

Anticoagulants (e.g., warfarin): Close monitoring of clotting time is necessary.
Corticosteroids (e.g., hydrocortisone):
Theophylline (for asthma).

Additionally, the effectiveness of antidiabetic medicines may be decreased, requiring a dose adjustment by your physician. Always inform your doctor or pharmacist of all prescription and non-prescription medicines, supplements, and herbal products you are taking.

Mechanism of Action

Climaston delivers 17β-estradiol and dydrogesterone, which modulate intracellular signaling by functioning as steroid hormone receptor ligands. 17β-estradiol acts as an agonist for the nuclear Estrogen Receptors (ER), primarily ERα and ERβ. Upon binding, the ligand-receptor complex translocates to the nucleus, where it binds to Estrogen Response Elements (EREs) on target gene promoters. This interaction modulates the transcription of specific genes, which consequently regulates protein synthesis in sensitive tissues like the endometrium, bone, and vascular smooth muscle.

Simultaneously, dydrogesterone, a synthetic retroprogesterone, functions as a highly selective agonist for the nuclear Progesterone Receptor (PR), binding to both PR-A and PR-B isoforms. Its major active metabolite, 20α-dihydrodydrogesterone (20α-DHD), also possesses progestogenic activity. Dydrogesterone's PR agonism induces a conformational change, leading to homodimerization and binding to Progesterone Response Elements (PREs), primarily in the endometrial tissue. This transcriptional modulation induces the transformation of the proliferative endometrial lining to a secretory state, functionally antagonizing the proliferative signaling cascade initiated by estrogen in that tissue. System-level consequences include the modulation of estrogen-responsive tissues via ER activation and counter-regulation of endometrial proliferation via PR activation.

Dosage and Administration Information

How Climaston is Used: Official Administration and Dosing

Climaston (Estradiol and Dydrogesterone) is a prescription Hormone Replacement Therapy (HRT) defined by precise, cyclical usage principles. The core dosing instruction is to use the lowest effective dose for the shortest duration consistent with treatment goals, with dosage adjustments based on clinical response.

Administration and Form

Climaston is strictly for oral administration and is supplied only as film-coated tablets. The tablet may be taken once daily, irrespectively of food intake, and should be taken at approximately the same time each day to maintain consistency.

Standard Dosing Regimens (28-Day Cycle)

Treatment is administered continuously in 28-day packs with no break between packs. The regimen used depends on the patient's menopausal status and presence of a uterus.

Regimen	Patient Status	Administration Schedule
Continuous Sequential	Women with an intact uterus who are perimenopausal or recently postmenopausal.	Days 1–14: Estrogen only. Days 15–28: Estrogen and Progestogen (e.g., Estradiol 1 mg and Dydrogesterone 10 mg).
Continuous Combined	Women confirmed to be at least 12 months post-menopause with an intact uterus.	Fixed combination of Estrogen and Progestogen (e.g., Estradiol 1 mg and Dydrogesterone 5 mg) taken daily.

Rules for Missed Doses and Use Over Time

If a dose is missed, it should be taken as soon as possible. However, if more than 12 hours have elapsed, the forgotten tablet must be discarded, and the patient should continue with the next scheduled dose. There is limited experience with its use in women older than 65 years, and the drug is not indicated for the pediatric population.

Recent Clinical Evidence

Research evidence / Overview of Studies for Climaston

This section provides an overview of the types of official research conducted on the combination of estradiol and dydrogesterone, focusing on the study designs and areas of uncertainty.

Evidence for Symptomatic Relief of Hot Flashes and Night Sweats

Research exploring symptoms of moderate-to-severe hot flashes and night sweats has primarily used short-term, randomized controlled trials (RCTs). These studies were applied in populations of postmenopausal women who still possessed an intact uterus. Researchers studied the combination against a placebo (an inactive treatment) and reported measured changes in the daily frequency and severity of vasomotor symptoms.

Findings describe patterns observed over the short-term study period, typically the first three months. Direct comparative evidence against all other active hormonal treatments remains lacking. This limits the long-term insight into the durability of reported changes for vasomotor symptoms.

Evidence for Bone Health and Osteoporosis Prevention

Research examining whether this combination was associated with changes in bone health involved intermediate- to long-term randomized studies, sometimes extending for two to three years. The primary research focus was to observe responses by measuring changes in Bone Mineral Density (BMD) at the lumbar spine and hip using specialized scans. Studies report measured changes in the observed populations, describing patterns that included the preservation or increase of BMD over the typical follow-up period.

Evidence examining fracture prevention is often based on patterns observed across the broader category of Hormone Replacement Therapy (HRT) and the measured association of the medication with BMD changes. Long-term outcomes and the necessary duration of continuous use to sustain these BMD measurements are not yet fully established across all research settings.

Evidence Gaps and Areas of Uncertainty

Research highlights areas where evidence is still emerging. For instance, data for long-term outcomes in women ge 65 years old are limited, as these cohorts were often underrepresented in the primary studies. Overall, the findings describe group patterns observed under specific study conditions, and research does not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Climaston (FAQ)

Q: Is it normal to experience irregular spotting or bleeding when first starting Climaston?

Irregular bleeding or spotting is frequently noted during the initial months of treatment, according to regulatory prescribing information. This is particularly common during the first three to six months of therapy. This pattern of bleeding is often anticipated by official guidance.

Q: How long does it typically take before I start to feel the effects of Climaston?

Studies focusing on the relief of symptoms, such as hot flashes, report measurable patterns of change over the short-term study period. Official research indicates that these symptomatic effects are often observed within the first three months of use.

Q: What is the longest period of time Climaston is generally studied for safe use?

Clinical research involving this combination has included studies that extend for up to two to three years, particularly when examining effects on bone health. Official documents state that data regarding long-term outcomes in women aged 65 years and older are limited.

Q: Is Climaston used to help prevent osteoporosis in postmenopausal women?

Official research has examined the association between this medication and changes in Bone Mineral Density (BMD), a finding that concerns bone health. Studies describe patterns that included the preservation or increase of BMD in the populations studied.

Q: What happens to the risk of blood clots when taking Climaston after long periods of immobility?

Official labeling documents that the use of combined estrogen-progestogen is associated with an increased risk of Venous Thromboembolism (VTE), or blood clots. This general risk can be influenced by other factors, including periods of immobility.

Q: Is Climaston considered a method of birth control?

Climaston is classified strictly as a Hormone Replacement Therapy (HRT) intended for the relief of menopausal symptoms. It is not defined or recommended in official documents as a method of contraception (birth control).

Q: If a person forgets a tablet, does this increase the chance of breakthrough bleeding?

If a dose is missed by more than 12 hours, official drug instructions specify that the forgotten tablet should be discarded. Regulatory information states that missing a dose can increase the likelihood of experiencing breakthrough bleeding or spotting.

Q: Why is it generally recommended to use Climaston at the lowest effective dose?

Official guidance recommends using the lowest effective dose for the shortest duration to minimize potential health risks associated with systemic combined hormone therapy. This is related to the documented risks of serious events like venous thromboembolism and stroke.

Q: Does Climaston contain 'bioidentical' hormones?

The active ingredients are Estradiol, which is chemically identical to the primary estrogen produced by the body, and Dydrogesterone, which is a synthetic progestogen. Official documents generally describe the drug by its chemical components, not by the marketing term 'bioidentical'.

Q: How does Climaston differ from other Hormone Replacement Therapy (HRT) types, like patches or gels?

Climaston is defined by its oral route of administration and is supplied only as film-coated tablets. Other types of Hormone Replacement Therapy (HRT) are available via different delivery methods, such as skin patches or gels.

Q: Does Climaston have a potential link to changes in weight, such as weight gain or loss?

Weight changes are listed in official prescribing information as a Common adverse reaction, meaning they may affect up to 1 in 10 patients. The official documentation notes the occurrence of changes but does not specify a single direction (gain or loss) in its general classification.

Q: Can taking Climaston affect the results of certain laboratory blood tests?

Systemic estrogen therapy can potentially affect the results of certain laboratory tests, including those related to thyroid function. This possibility is noted in the prescribing information for hormone replacement therapies.

Q: What does official research say about Climaston's effects on bone mineral density?

Official research focusing on bone health has reported measured patterns in study populations that included the preservation or increase of Bone Mineral Density (BMD) at the lumbar spine and hip over the typical follow-up period.

Q: What kind of irregular bleeding should be reported to a healthcare provider while on Climaston?

Official warnings advise that unscheduled bleeding or spotting that persists for longer than the first six months, begins after an established period of no bleeding, or recurs after stopping therapy, must be reviewed by a healthcare professional.

Q: Can patients who have migraine headaches use Climaston?

Headache is a very common side effect listed in prescribing information. Furthermore, the use of combined hormone therapy may potentially exacerbate pre-existing conditions like migraine, which is a factor associated with hormone therapy.

Q: Do studies suggest a possible increase in the risk of gallbladder issues with drugs like Climaston?

Official warnings for oral hormone replacement therapy state that the use of estrogen-containing medications is associated with a potential increase in the risk of developing gallbladder disease requiring surgery.

Q: What is the concern regarding smoking while taking hormone therapy like Climaston?

Smoking is identified as a known risk factor that can significantly increase the risk of serious side effects, such as venous thromboembolism (blood clots) and other cardiovascular events, when combined with oral hormone replacement therapy.

Q: Do regulatory agencies recommend regular check-ups while taking Climaston?

Regulatory guidelines recommend that patients undergo periodic medical examinations to determine the appropriate duration and need for continuing therapy. Specific health indicators like blood pressure should also be monitored at regular intervals.

Q: Is there evidence concerning Climaston's potential effects on sleep disturbances?

Official research has examined the drug's effects on symptoms like night sweats, which are linked to sleep disruption in menopausal women.

Q: What are some of the signs of a blood clot that are often mentioned in official drug warnings?

Official warnings advise patients to be vigilant for signs that may indicate a blood clot. These include symptoms such as pain and swelling in the leg, sudden chest pain, or shortness of breath.

Q: Is there any information on how long side effects like nausea usually last when starting Climaston?

Side effects like nausea are commonly reported when first starting estrogen-containing medications. Regulatory information indicates that these effects typically improve or resolve within the initial one to three months of use.

Q: Is there any mention of Climaston affecting energy levels or causing fatigue?

Fatigue and tiredness are sometimes reported as adverse reactions associated with hormone replacement therapy. This may be a factor that resolves over the initial months of use.

Q: What are the general population risk factors that can affect the safety profile of Climaston?

The overall safety profile of combined hormone therapy is influenced by individual health factors. These factors include a personal or family history of blood clots, breast cancer, or a history of high blood pressure or smoking.

How should Climaston be stored and disposed of?

How to Store and Dispose of Climaston

Climaston (estradiol/dydrogesterone) storage and disposal must strictly follow the requirements documented in official regulatory labeling.

Storage Requirements

Storage Component	Official Requirement
Temperature	Does not require any special temperature storage conditions.
Protection	Store in the original container and outer carton to protect the tablets from light and moisture.
Child Safety	Keep the medicine out of the sight and reach of children.
Stability	Do not use the medicine after the expiry date (EXP) printed on the packaging.

Disposal Instructions

Official disposal rules forbid discarding Climaston via wastewater or household waste, as the product may pose a risk to the aquatic environment. Unused or expired medicine must be returned to a pharmacist for proper pharmaceutical waste management.

Climaston